Carrie Northcott

I highly recommend reading this excellent article highlighting the 10 year anniversary of the IO drugs that transformed cancer and its impact on patients and the industry. #checkpointinhibitors #cancer https://lnkd.in/eh4nP27D

30

2 Comments

Come visit me at the poster session of BioTechX tomorrow in Philly! My poster is called "Identification and Annotation of Publicly Available Single Cell RNA-sequencing Data". Rancho BioSciences #biotechxphilly #biotechx 

12

Very interesting article to have a close look into the researchers' world - including the timelines for Drug Discovery and Development: Stages, Failure Rates, and Improvement Strategies. As a biobank, surely there are some things we can do to help.

4

CAR T cells have proven successful in clinical trials for blood cancers, and researchers are eager to apply the technology to other types of cancers and diseases. If your R&D strategy is leading you toward leveraging CAR T, you need this new white paper:

10

Day 3 of Team Interius making us proud at American Society of Gene & Cell Therapy in Baltimore! Stop by & see some of our poster presentations in person, or view them online: https://lnkd.in/eKiSKA4 Abstract Number 2. In Vivo Generation of Both CAR T Cells and CAR NK Cells Using a CD7 Abstract Number 201. Rational Design of a Detargeted Vesiculovirus Fusogen to Enable Targeted In Vivo Gene Delivery Abstract Number 235. Pharmacokinetics and Vector Shedding in NHPs Following a Single Intravenous Infusion of a CD20-Targeted Engineered Lentiviral Vector Abstract Number 1360. Automating a Lentivirus Infectious Titer Assay (ITA) Abstract Number1361. Evaluation of Residual Host Cell DNA Clearance and Sizing During Production of a Lentiviral Vector Abstract Number 1839. In Vivo Delivery of an Engineered Lentiviral CAR19 Vector for the Treatment of Autoimmune Diseases #asgct #asgct2024 #phillybio

90

1 Comment

We're building the first-of-a-kind #Dynamic #PDB to capture generalized protein motions (GPCRs, kinases, proteases, TNF, etc.) at scale for targets involved in #immunooncology, and #neurodegeneration. Key highlights: 1. Predict functionally relevant conformational states for protein-protein interactions. 2. Accurately predict population shifts from mutations and ligand binding. 3. Scalable prediction of #allostery. 4. Predict cryptic pockets & novel therapeutic modalities (#glues, #PROTACs). 5. Train AI models to predict 'functionally relevant' conformational ensembles from sequences across protein classes. Coming to a preprint server near you! If you are curious about developing selective therapeutics and how to modulate protein-protein interactions, feel free to reach out to Shray V. or me. #AI #DrugDiscovery #StructuralBiology #ProteinDynamics

125

2 Comments

Antibiotics are used to treat BV and UTI, but recurrences are common. Antibiotics inhibit or kill the bacteria that cause these conditions, but and they do not prevent recurrence since they do not restore protective Lactobacillus. To address this unmet medical need, Osel developed a proprietary Live Biotherapeutic Product (LBP), called LACTIN-V that contains the protective vaginal strain, Lactobacillus crispatus CTV-05. L. crispatus CTV-05 produces lactic acid and hydrogen peroxide, adheres to vaginal epithelial cells, and antagonizes bacteria associated with BV and uropathogenic E. coli, which is responsible for most UTIs. LACTIN-V has also been shown to reduce preterm birth.

27

COTA and the FDA will advance #cancerresearch using #realworlddata, focusing on #regulatory decision-making and improving treatment evaluation and availability. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #healthdata

25

University of Pennsylvania Gene Therapy Spinout Interius BioTherapeutics Doses Patient, Achieves CAR Therapy First Interius BioTherapeutics, a Penn spinout company co-founded by Saar Gill, MD, PhD, an associate professor of Hematology-Oncology, recently announced treatment of the first patient in a clinical trial of a new CAR T cell therapy. The method of manufacturing CAR T cells that was developed at Penn Medicine by Carl June, MD, the Richard W. Vague Professor in Immunotherapy, and Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy, involves engineering cells from a patient in the lab, then reinfusing them. The new approach is testing an in vivo method, where the CAR T cells are made directly in the patient’s body. #PennMedicine https://lnkd.in/efTJyVWc

8